MedTrace Logo

Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study

NCT03152097 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2019-09-24

No results posted yet for this study

Summary

The project will investigate the modulation of flavin-containing monooxygenase (FMO) formation of the CVD risk factor trimethylamine-N-oxide (TMAO) in patients with kidney disease.

Conditions

Interventions

DIETARY_SUPPLEMENT

Commercially available Diindolylmethane

Commercially available Diindolylmethane is a compound derived from cruciferous vegetables (e.g. broccoli)

OTHER

Placebo

A matching placebo capsule will be compounded by the UPMC Investigational Drug Service

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Thomas D Nolin, PharmD, PhD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-30
Primary Completion
2019-04-18
Completion
2019-08-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03152097 on ClinicalTrials.gov